KalVista Pharmaceuticals stock holds at $15.20 as investors await data

Published on 09/23/2026 at 02:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

KalVista Pharmaceuticals stock closed at USD 15.20 on September 22, 2026, with a market value of USD 420 million. The company reported USD 38.6 million in Q2 revenue.

KALV, US48530T1051, Illustration mit AI erstellt.

KalVista Pharmaceuticals, Inc. (ISIN US48530T1051) closed at USD 15.20 on Nasdaq on September 22, 2026, while its market capitalization stood at USD 420 million. The latest reported figures give the stock a measurable operating base as investors assess the company's treatment pipeline.

Stock trades near its yearly range

The September 22, 2026 Nasdaq quotation covered a 52-week range of USD 8.75 to USD 19.40, leaving the closing price USD 6.45 above the low and USD 4.20 below the high. Volume reached 1,245,600 shares, providing a dated reference for the market's current valuation.

The stock therefore stood 22.0 percent below its 52-week high on September 22, 2026. That comparison places the USD 15.20 close closer to the upper half of the annual range than to the low, while the USD 420 million market capitalization keeps the company in small-cap biotechnology territory.

Quarterly revenue provides the operating base

KalVista reported revenue of USD 38.6 million for the second quarter of fiscal 2026, according to the company's investor-relations materials dated September 2026. The figure supplies the latest period-specific revenue reference for assessing commercial progress.

For the same second quarter of fiscal 2026, KalVista reported a net loss of USD 24.8 million, or USD 0.87 per diluted share, according to the company. Revenue and earnings therefore point in different directions: commercial income provides scale, while the quarterly loss shows that research, development and commercialization costs remain material.

Price and latest market snapshot

KalVista Pharmaceuticals stock closed at USD 15.20 on Nasdaq on September 22, 2026. The corresponding 52-week range was USD 8.75 to USD 19.40, and the dated market capitalization was USD 420 million.